NZ306510A
(en)
*
|
1995-05-01 |
1999-05-28 |
Scotia Holdings Plc |
Niacin derivatives which include a fatty acid or fatty acid alcohol residue and their use in medicaments and skin care compositions
|
MY118354A
(en)
*
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
USRE40546E1
(en)
*
|
1996-05-01 |
2008-10-21 |
Scarista, Ltd. |
1,3-Propane diol esters and ethers and methods for their use in drug delivery
|
US6576636B2
(en)
*
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
US6255347B1
(en)
|
1996-06-21 |
2001-07-03 |
Advanced Research And Technology Institute |
Methods and compositions comprising R-ibuprofen
|
CN1237162A
(zh)
*
|
1996-11-12 |
1999-12-01 |
美国家用产品公司 |
Cox-2的茚抑制剂
|
US5869524A
(en)
*
|
1996-11-12 |
1999-02-09 |
American Home Products Corporation |
Indene inhibitors of COX-2
|
AU5727798A
(en)
*
|
1996-12-23 |
1998-07-17 |
Texas A & M University, The |
Anti-amyloidogenic agents
|
WO1998046588A2
(en)
*
|
1997-04-11 |
1998-10-22 |
Neorx Corporation |
Compounds and therapies for the prevention of vascular and non-vascular pathologies
|
ES2302373T3
(es)
*
|
1998-02-13 |
2008-07-01 |
Nutramax Laboratories, Inc. |
Agentes y metodos para la proteccion, tratamiento y reparacion de tejidos conectivos.
|
US7413759B2
(en)
*
|
1998-05-21 |
2008-08-19 |
Beech-Nut Nutrition Corporation |
Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
|
US6579551B1
(en)
|
1998-05-21 |
2003-06-17 |
Beech-Nut Nutrition Corporation |
Baby-food compositions containing egg yolk and methods therefor
|
US7141266B2
(en)
*
|
1998-05-21 |
2006-11-28 |
Beech-Nut Nutrition Corporation |
Baby-food compositions enhancing visual acuity and methods therefor
|
US6149964A
(en)
*
|
1998-05-21 |
2000-11-21 |
Beech-Nut Nutrition Corporation |
Egg yolk-containing baby food compositions and methods therefor
|
US20040073258A1
(en)
*
|
1999-01-06 |
2004-04-15 |
Church W. Edward |
Body tissue and skin treatment method using pulsing heating pad and topical cream
|
US6572871B1
(en)
*
|
1999-01-06 |
2003-06-03 |
W. Edward Church |
Pain treatment method and apparatus using heating wrap and analgesic cream
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
US7235583B1
(en)
*
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
US6426367B1
(en)
*
|
1999-09-09 |
2002-07-30 |
Efa Sciences Llc |
Methods for selectively occluding blood supplies to neoplasias
|
AU5702201A
(en)
*
|
2000-04-13 |
2001-10-30 |
Mayo Foundation |
Abeta<sub>42</sub> lowering agents
|
US20060004086A1
(en)
*
|
2000-04-13 |
2006-01-05 |
Mayo Foundation For Medical Education And Research |
Method of reducing Abeta42 and treating diseases
|
US6306842B1
(en)
*
|
2000-06-02 |
2001-10-23 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
AU2001275036A1
(en)
*
|
2000-06-02 |
2001-12-17 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
WO2002009725A1
(en)
*
|
2000-08-02 |
2002-02-07 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases
|
US6927239B1
(en)
*
|
2000-08-02 |
2005-08-09 |
Pharmanutrients |
Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
|
US6838451B1
(en)
|
2000-08-02 |
2005-01-04 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases
|
US7208522B1
(en)
|
2000-08-02 |
2007-04-24 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of Syndrome X
|
US20020094970A1
(en)
*
|
2000-12-14 |
2002-07-18 |
Ronenn Roubenoff |
Compositions and methods for treating an arthritic condition
|
JP4634694B2
(ja)
*
|
2001-03-23 |
2011-02-16 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪アルコール薬物複合体
|
EP1427407A4
(en)
*
|
2001-03-23 |
2005-05-11 |
Luitpold Pharm Inc |
CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS
|
GB0111282D0
(en)
*
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
JP3977162B2
(ja)
*
|
2002-06-21 |
2007-09-19 |
株式会社バンダイナムコゲームス |
キャラクタ情報管理装置、プログラム及び情報記憶媒体
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
JP2007528857A
(ja)
*
|
2003-07-11 |
2007-10-18 |
ミリアド ジェネティクス, インコーポレイテッド |
アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
|
US20050154059A1
(en)
*
|
2004-01-13 |
2005-07-14 |
Cook Mark E. |
Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
|
US20090155903A1
(en)
*
|
2004-03-19 |
2009-06-18 |
Myriad Genetics, Incorporated |
Pharmaceutical composition and method
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
AU2005241023A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Keystone Retaining Wall Systems, Inc. |
Veneers for walls, retaining walls and the like
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020853A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US20090318394A1
(en)
*
|
2004-11-19 |
2009-12-24 |
Julie Nauroth |
Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
|
US7893106B2
(en)
*
|
2004-11-19 |
2011-02-22 |
Martek Biosciences, Corporation |
Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
|
JP2008520739A
(ja)
*
|
2004-11-19 |
2008-06-19 |
マーテック・バイオサイエンシーズ・コーポレーション |
長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製および使用方法
|
US20070042034A1
(en)
*
|
2005-07-22 |
2007-02-22 |
Myriad Genetics, Incorporated |
High drug load formulations and dosage forms
|
WO2007090162A2
(en)
*
|
2006-01-31 |
2007-08-09 |
Martek Biosciences Corporation |
OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
|
WO2008006099A2
(en)
*
|
2006-07-07 |
2008-01-10 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
US20110190389A1
(en)
*
|
2007-02-20 |
2011-08-04 |
Linda Arterburn |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
WO2008153722A1
(en)
*
|
2007-05-22 |
2008-12-18 |
The Board Of Regents Of The University Of Texas System |
Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
|
WO2009086281A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Martek Biosciences Corporation |
Method for preparation of oxylipins
|
US9085527B2
(en)
*
|
2008-07-08 |
2015-07-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid acylated salicylates and their uses
|
WO2010006085A1
(en)
|
2008-07-08 |
2010-01-14 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid acetylated salicylates and their uses
|
ES2862336T3
(es)
|
2008-09-02 |
2021-10-07 |
Amarin Pharmaceuticals Ie Ltd |
Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
|
WO2010033726A2
(en)
*
|
2008-09-17 |
2010-03-25 |
The Brigham And Women's Hospital, Inc. |
Drug delivery composition comprising a self-assembled gelator
|
WO2010077422A2
(en)
|
2008-10-29 |
2010-07-08 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
RU2553214C2
(ru)
|
2008-10-29 |
2015-06-10 |
Аблинкс Н.В. |
Способы очистки однодоменных антигенсвязывающих молекул
|
CA2751576C
(en)
|
2009-02-10 |
2018-07-03 |
Amarin Pharma, Inc. |
Use of eicosapentaenoic acid to treat hypertriglyceridemia
|
KR101357438B1
(ko)
|
2009-04-29 |
2014-02-06 |
아마린 코포레이션 피엘씨 |
Epa 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법
|
SI2424356T1
(en)
|
2009-04-29 |
2018-01-31 |
Armarin Pharmaceuticals Ireland Limited |
A stable pharmaceutical composition and procedures for its use
|
MY172372A
(en)
|
2009-06-15 |
2019-11-21 |
Amarin Pharmaceuticals Ie Ltd |
Compositions and methods for lowering triglycerides
|
USRE46608E1
(en)
|
2009-09-01 |
2017-11-14 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid niacin conjugates and their uses
|
DK2473045T3
(en)
|
2009-09-01 |
2016-12-12 |
Catabasis Pharmaceuticals Inc |
Niacin-FATTY ACID CONJUGATES AND THEIR USES
|
US20110064813A1
(en)
*
|
2009-09-16 |
2011-03-17 |
Charles Vaughn |
Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet
|
EP2480248B1
(en)
|
2009-09-23 |
2015-09-02 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
CN104586859B
(zh)
|
2009-12-31 |
2017-12-05 |
凯姆制药公司 |
喹硫平的氨基酸缀合物、其制备和使用方法
|
CN102822141A
(zh)
*
|
2010-01-20 |
2012-12-12 |
普罗诺瓦生物医药挪威公司 |
水杨酸脂肪酸衍生物
|
WO2011109724A1
(en)
*
|
2010-03-04 |
2011-09-09 |
Amarin Pharma, Inc. |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US9216224B2
(en)
|
2010-03-05 |
2015-12-22 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid COX inhibitor derivatives and their uses
|
TR201900067T4
(tr)
|
2010-03-11 |
2019-02-21 |
Kempharm Inc |
Ketiyapinin yağ asidi konjugatları, bunların yapılmasına ve kullanılmasına yönelik proses.
|
US20130045939A1
(en)
*
|
2010-03-19 |
2013-02-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid macrolide derivatives and their uses
|
CN108314733A
(zh)
*
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
JP2013540757A
(ja)
|
2010-09-24 |
2013-11-07 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
EP2646013A4
(en)
|
2010-11-29 |
2014-03-26 |
Amarin Pharma Inc |
COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
|
AU2011349718B2
(en)
*
|
2010-12-21 |
2017-02-09 |
Nestec S.A. |
Methods and compositions for preventing and treating osteoarthritis
|
KR102188840B1
(ko)
|
2011-09-29 |
2020-12-10 |
피엘엑스 옵코 인코포레이티드 |
위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
EP2800469B1
(en)
|
2012-01-06 |
2021-08-25 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
|
MX2020008890A
(es)
|
2012-06-29 |
2022-08-15 |
Amarin Pharmaceuticals Ie Ltd |
Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
IL282010B
(en)
|
2013-12-24 |
2022-07-01 |
Univ Virginia Commonwealth |
Uses of oxidized cholesterol sulfates
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US9603869B2
(en)
|
2015-05-22 |
2017-03-28 |
University Of South Florida |
Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
|
AU2016335846B2
(en)
|
2015-10-08 |
2019-04-04 |
The Brigham And Women's Hospital, Inc. |
Stabilized assembled nanostructures for delivery of encapsulated agents
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
CN115837006A
(zh)
|
2016-05-06 |
2023-03-24 |
布里格姆及妇女医院股份有限公司 |
用于向软骨中受控递送被囊封的药剂的二元自组装凝胶
|
US11020410B2
(en)
|
2017-02-03 |
2021-06-01 |
The Brigham And Women's Hospital, Inc. |
Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
|
JP7211974B2
(ja)
|
2017-05-08 |
2023-01-24 |
アリヴィオ セラピューティクス, インコーポレイテッド |
増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
JP7020756B2
(ja)
|
2018-09-24 |
2022-02-16 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
対象の心血管イベントのリスクを低減する方法
|
MX2022011743A
(es)
|
2020-03-26 |
2022-12-08 |
Plx Opco Inc |
Portadores farmaceuticos con capacidad de reconstitucion dependiente del ph y metodos para elaborar y usar los mismos.
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|